한글목차

세계 비경구약 시장 전망은 병원 및 의료센터에서 시장 기회로 인해 유망한 것으로 전망되고 있습니다. 세계 비경구약 시장은 2025-2031년 연평균 복합 성장률(CAGR) 4.1%를 보일 것으로 예측됩니다. 이 시장의 주요 촉진요인은 바이오 치료에 대한 수요 증가, 만성 질환의 유병률 증가, 주사제 채택 확대 등입니다.

• Lucintel의 예측에 따르면, 유형별로는 LVP 약품이 예측 기간 동안 높은 성장세를 보일 것으로 예측됩니다.
• 용도별로는 의료센터용이 높은 성장이 예상됩니다.
• 지역별로는 아시아태평양이 예측 기간 동안 가장 높은 성장을 보일 것으로 예측됩니다.

비경구약 시장의 새로운 트렌드

비경구약 시장은 과학적 혁신, 환자 니즈의 진화, 약물 전달 기술의 발전에 힘입어 큰 변화의 시기를 맞이하고 있습니다. 이러한 새로운 트렌드는 의약품 제조와 환자 치료의 미래를 형성하고 있습니다.

• 생물학적 제제 및 바이오시밀러의 부상: 단일클론항체, 유전자치료제, 세포치료제 등 생물학적 제제의 개발 및 승인 증가는 큰 추세입니다. 이러한 고분자 의약품은 비경구 투여가 필요한 경우가 많기 때문에 그 성장은 주사제 및 첨단 전달 시스템에 대한 수요를 직접적으로 촉진하고 있습니다.
• 환자 중심 전달 장치: 가정 내 자가 투여를 위해 사용하기 쉬운 비경구 약물 전달 장치를 개발하는 경향이 강합니다. 프리필드시린지, 자동주사기, 웨어러블 주사기 등의 기술 혁신은 환자의 복약 순응도, 편의성을 향상시키고, 특히 만성질환의 경우 의료시설의 부담을 경감시켜주고 있습니다.
• 장기지속형 주사제: 이 시장에서는 투여 횟수를 줄이고 환자의 순응도를 높이는 장기지속형 주사제에 대한 관심이 높아지고 있습니다. LAI는 특히 정신분열증, 당뇨병, HIV 등 만성질환 관리에 도움이 되며, 약물의 서방형을 가져와 치료 효과를 높입니다.
• 무균 제조의 발전: 생물학적 제제의 복잡성이 증가하고 고역가 화합물이 요구됨에 따라 무균 처리 및 무균 제조 기술의 발전은 매우 중요합니다. 여기에는 아이솔레이터 기술, 로봇 충전 마감 라인 채택, 제품의 안전과 무결성을 보장하기 위한 엄격한 품질 관리 등이 포함됩니다.
• 맞춤의료와 표적치료: 환자 개개인프로파일에 맞추어 치료하는 맞춤의료로의 전환은 종종 특이성이 높은 약물의 비경구 투여를 수반합니다. 이러한 추세는 소량 생산 능력과 표적 치료를 위한 특수 전달 시스템에 대한 수요를 촉진합니다.

이러한 추세는 복잡하고 고부가가치의 치료제 개발을 촉진하고, 혁신적인 전달 방법을 통해 환자의 편의성을 높이고, 치료 순응도를 향상시키며, 무균 제조 공정의 발전을 촉진함으로써 비경구용 의약품 시장을 크게 재편하고 있습니다.

비경구약 시장의 최근 동향

비경구약 시장은 전 세계적으로 만성질환 증가와 약학의 발전에 힘입어 강력한 성장과 끊임없는 기술 혁신을 경험하고 있습니다. 이러한 개발로 인해 약물의 효과, 환자의 편의성, 전반적인 의료 서비스 제공이 향상되고 있습니다.

• 생물학적 제제 개발 증가: 단일클론항체, 첨단 치료제 등 생물학적 제제의 연구개발 및 승인이 급증하고 있는 것도 큰 진전입니다. 이러한 복잡한 분자는 주로 비경구 투여가 필요하기 때문에 특수 주사제 및 정교한 전달 솔루션에 대한 수요가 직접적으로 증가하고 있습니다.
• 환자 자가 투약 장치: 가정용으로 설계된 사용하기 편리한 비경구 투여용 장치의 보급이 두드러지게 증가하고 있습니다. 프리필드시린지, 자동주사기, 웨어러블 주사기 등이 보편화되고 있으며, 환자가 편리하게 약물을 자가 투여할 수 있도록 함으로써 치료 순응도를 높이고 의료비용을 절감하고 있습니다.
• 무균 제조의 발전: 최근 동향은 아이솔레이터 기술, 로봇 충전 마감 라인의 채택 등 무균 제조 능력의 지속적인 향상을 강조하고 있습니다. 이를 통해 주사제의 무균성과 품질을 보다 높은 수준으로 보장할 수 있으며, 이는 고감도 생물학적 제제 및 고역가 화합물에 매우 중요한 요소로 작용합니다.
• 지속형 제제에 집중: 지속형 주사제 개발은 최근 중요한 트렌드입니다. 이러한 혁신적인 제제는 주사 횟수를 줄이고, 환자의 순응도를 높이며, 만성 질환 관리를 위한 치료 효과를 지속시키고, 환자 예후에 긍정적인 영향을 미칩니다.
• CMO의 확대: CMO는 비경구 제제 제조 능력과 전문성을 크게 확장하고 있습니다. 이러한 발전으로 제약회사는 복잡한 무균 충전 및 마무리 작업을 아웃소싱할 수 있으며, 특히 중소규모의 생명공학 기업의 경우 의약품 개발 및 상용화를 가속화할 수 있습니다.

이러한 움직임은 치료 가능한 질환의 확대, 환자 접근성 및 편의성 향상, 제품 품질 향상, 복약 순응도 개선, 의약품 개발 및 제조 공정의 간소화 등 비경구용 의약품 시장에 큰 영향을 미치고 있습니다.

목차

제1장 주요 요약

제2장 시장 개요

• 배경과 분류
• 공급망

제3장 시장 동향과 예측 분석

• 업계 촉진요인과 과제
• PESTLE 분석
• 특허 분석
• 규제 환경

제4장 세계의 비경구약 시장 : 유형별

• 개요
• 매력 분석 : 유형별
• LVP약 : 동향과 예측(2019-2031년)
• SVP약 : 동향과 예측(2019-2031년)

제5장 세계의 비경구약 시장 : 용도별

• 개요
• 매력 분석 : 용도별
• 병원 : 동향과 예측(2019-2031년)
• 의료센터 : 동향과 예측(2019-2031년)
• 기타 : 동향과 예측(2019-2031)

제6장 지역 분석

• 개요
• 세계의 비경구약 시장 : 지역별

제7장 북미의 비경구약 시장

• 개요
• 북미의 비경구약 시장 : 유형별
• 북미의 비경구약 시장 : 용도별
• 미국의 비경구약 시장
• 멕시코의 비경구약 시장
• 캐나다의 비경구약 시장

제8장 유럽의 비경구약 시장

• 개요
• 유럽의 비경구약 시장 : 유형별
• 유럽의 비경구약 시장 : 용도별
• 독일의 비경구약 시장
• 프랑스의 비경구약 시장
• 스페인의 비경구약 시장
• 이탈리아의 비경구약 시장
• 영국의 비경구약 시장

제9장 아시아태평양의 비경구약 시장

• 개요
• 아시아태평양의 비경구약 시장 : 유형별
• 아시아태평양의 비경구약 시장 : 용도별
• 일본의 비경구약 시장
• 인도의 비경구약 시장
• 중국의 비경구약 시장
• 한국의 비경구약 시장
• 인도네시아의 비경구약 시장

제10장 기타 지역(ROW)의 비경구약 시장

• 개요
• 기타 지역 의 비경구약 시장 : 유형별
• 기타 지역 의 비경구약 시장 : 용도별
• 중동의 비경구약 시장
• 남미의 비경구약 시장
• 아프리카의 비경구약 시장

제11장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter의 Five Forces 분석
  • 경쟁 기업간 경쟁 관계
  • 바이어의 교섭력
  • 공급업체의 교섭력
  • 대체품의 위협
  • 신규 진출업체의 위협
• 시장 점유율 분석

제12장 기회와 전략 분석

• 밸류체인 분석
• 성장 기회 분석
  • 성장 기회 : 유형별
  • 성장 기회 : 용도별
• 세계의 비경구약 시장의 새로운 동향
• 전략 분석
  • 신제품 개발
  • 인증 및 라이선싱
  • 인수합병(M&A), 계약, 제휴 및 합작투자(JV)

제13장 밸류체인 주요 기업 개요

• 경쟁 분석
• Ostuka Pharmaceutical
• Teva Pharmaceutical Industries
• Kelun Pharma
• Cook Pharmica
• Patheon
• BAG Healthcare
• Beximco Pharma
• Baxter Healthcare Corporation
• B. Braun
• Fresenius

제14장 부록

• 그림 리스트
• 표 리스트
• 분석 방법
• 면책사항
• 저작권
• 약어와 기술 단위
• Lucintel에 대해
• 문의

영문목차

The future of the global parenteral drug market looks promising with opportunities in the hospital and medical center markets. The global parenteral drug market is expected to grow with a CAGR of 4.1% from 2025 to 2031. The major drivers for this market are the increasing demand for biologic therapies, the rising prevalence of chronic diseases, and the growing adoption of injectable drugs.

• Lucintel forecasts that, within the type category, LVP drug is expected to witness higher growth over the forecast period.
• Within the application category, medical center is expected to witness higher growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Parenteral Drug Market

The parenteral drug market is undergoing significant transformation, driven by scientific breakthroughs, evolving patient needs, and advancements in drug delivery technologies. These emerging trends are shaping the future of pharmaceutical manufacturing and patient care.

• Rise of Biologics and Biosimilars: The increasing development and approval of biologic drugs, including monoclonal antibodies, gene therapies, and cell therapies, are a major trend. As these large-molecule drugs often require parenteral administration, their growth directly fuels the demand for injectable formulations and advanced delivery systems.
• Patient-Centric Delivery Devices: There's a strong trend towards developing user-friendly parenteral drug delivery devices for self-administration at home. Innovations like prefilled syringes, auto-injectors, and wearable injectors are improving patient adherence, convenience, and reducing the burden on healthcare facilities, especially for chronic conditions.
• Long-Acting Injectables: The market is seeing a growing emphasis on long-acting injectable formulations that reduce dosing frequency and improve patient compliance. LAIs are particularly beneficial for managing chronic diseases like schizophrenia, diabetes, and HIV, offering sustained drug release and enhancing therapeutic outcomes.
• Sterile Manufacturing Advancements: With the increasing complexity of biologic drugs and the need for high-potency compounds, advancements in aseptic processing and sterile manufacturing technologies are critical. This includes the adoption of isolator technology, robotic fill-finish lines, and stringent quality control to ensure product safety and integrity.
• Personalized Medicine & Targeted Therapies: The shift towards personalized medicine, where treatments are tailored to individual patient profiles, often involves parenteral administration of highly specific drugs. This trend drives demand for small-batch manufacturing capabilities and specialized delivery systems for targeted therapies.

These trends are significantly reshaping the parenteral drug market by fostering the development of complex and high-value therapeutics, enhancing patient convenience through innovative delivery methods, improving treatment adherence, and driving advancements in sterile manufacturing processes.

Recent Developments in the Parenteral Drug Market

The parenteral drug market is experiencing robust growth and continuous innovation, driven by the increasing global burden of chronic diseases and advancements in pharmaceutical science. These developments are enhancing drug efficacy, patient convenience, and overall healthcare delivery.

• Increased Biologic Drug Development: A significant development is the surge in research, development, and approval of biologic drugs, including monoclonal antibodies and advanced therapies. These complex molecules primarily require parenteral administration, directly fueling demand for specialized injectable formulations and sophisticated delivery solutions.
• Patient Self-Administration Devices: There's a notable development in the proliferation of user-friendly parenteral devices designed for home use. Prefilled syringes, auto-injectors, and wearable injectors are becoming more common, empowering patients to self-administer medications conveniently, thereby improving treatment adherence and reducing healthcare costs.
• Advancements in Sterile Manufacturing: Recent developments highlight continuous improvements in sterile manufacturing capabilities, including the adoption of isolator technologies and robotic fill-finish lines. This ensures higher levels of sterility and quality for injectable drugs, crucial for sensitive biologics and high-potency compounds.
• Focus on Long-Acting Formulations: The development of long-acting injectable formulations is a key recent trend. These innovative formulations reduce the frequency of injections, offering improved patient compliance and sustained therapeutic effects for chronic disease management, impacting patient outcomes positively.
• Expansion of Contract Manufacturing Organizations: CMOs are significantly expanding their parenteral manufacturing capacities and expertise. This development allows pharmaceutical companies to outsource complex sterile fill-finish operations, accelerating drug development and commercialization, especially for small and mid-sized biotech firms.

These developments are profoundly impacting the parenteral drug market by expanding the range of treatable conditions, enhancing patient access and convenience, ensuring higher product quality, improving adherence to medication regimens, and streamlining the drug development and manufacturing processes.

Strategic Growth Opportunities in the Parenteral Drug Market

The parenteral drug market offers substantial strategic growth opportunities across various applications, driven by evolving medical needs, technological advancements, and a focus on patient convenience. Capitalizing on these opportunities is key for market players.

• Oncology and Autoimmune Diseases: The high prevalence of cancer and autoimmune disorders, coupled with the increasing development of targeted biologic therapies, presents significant growth. Parenteral administration is crucial for these high-potency drugs, making this a prime area for specialized injectable formulations and delivery devices.
• Chronic Disease Management: The rising global burden of chronic conditions like diabetes, cardiovascular diseases, and neurological disorders offers a major opportunity. Developing long-acting injectables and user-friendly self-administration devices for these conditions can improve patient adherence and quality of life, driving market expansion.
• Vaccines and Gene Therapies: The ongoing development of new vaccines and the emergence of gene therapies represent a high-growth segment. These often require precise parenteral delivery, creating opportunities for advanced prefilled syringes, multi-dose vials, and novel delivery platforms to ensure effective administration.
• Home Healthcare and Self-Administration: The shift towards home-based care for many conditions creates a strong opportunity for parenteral drugs designed for patient self-administration. Investing in ergonomic auto-injectors, wearable pumps, and supportive digital health solutions can capture this expanding market segment.
• Biosimilar Development and Manufacturing: As patents for various biologics expire, the biosimilar market is booming, often requiring parenteral administration. Focusing on efficient and cost-effective manufacturing of biosimilar injectables, including fill-finish services, presents a significant opportunity for both pharmaceutical companies and CMOs.

These strategic growth opportunities are significantly impacting the parenteral drug market by fostering innovation in high-demand therapeutic areas, enhancing patient accessibility and adherence through convenient delivery systems, and driving the development of cost-effective alternatives in critical drug categories.

Parenteral Drug Market Driver and Challenges

The parenteral drug market is influenced by a dynamic interplay of various technological, economic, and regulatory factors. These elements serve as both significant drivers propelling market expansion and crucial challenges that necessitate strategic responses from industry participants.

The factors responsible for driving the parenteral drug market include:

1. Increasing Chronic Disease Prevalence: The global rise in chronic diseases such as cancer, diabetes, and autoimmune disorders significantly drives the parenteral drug market. These conditions often require long-term treatment with high-potency drugs best delivered via injection, ensuring effective and reliable therapeutic outcomes.

2. Growth of Biologics and Biosimilars: The escalating development and market penetration of complex biologic drugs (e.g., monoclonal antibodies, cell and gene therapies) and their biosimilar counterparts is a major driver. Due to their molecular structure, these therapies almost exclusively require parenteral administration, fueling demand for injectables.

3. Technological Advancements in Delivery Systems: Innovations in parenteral drug delivery, including prefilled syringes, auto-injectors, and wearable injectors, enhance patient convenience, safety, and adherence. These advancements facilitate self-administration, reduce healthcare burden, and significantly expand the market.

4. Rising Geriatric Population: The global increase in the elderly population contributes to market growth, as older individuals are more susceptible to chronic diseases requiring parenteral treatments. Additionally, parenteral administration can be easier for patients with swallowing difficulties or impaired gastrointestinal absorption.

5. Increased Focus on Personalized Medicine: The shift towards personalized and targeted therapies often involves highly potent drugs delivered parenterally to specific sites or patient subsets. This trend drives demand for customized injectable formulations and precision delivery systems, enhancing treatment efficacy.

Challenges in the parenteral drug market are:

1. High Manufacturing Costs: The production of parenteral drugs demands stringent sterile environments, specialized equipment, and complex quality control processes. These requirements lead to significantly higher manufacturing costs compared to oral solid dosage forms, impacting profitability and product pricing.

2. Stringent Regulatory Requirements: Parenteral drugs are subject to very strict regulatory oversight due to their direct entry into the bloodstream, necessitating rigorous testing for sterility, pyrogens, and particulate matter. Navigating diverse and evolving global regulations poses a significant challenge for manufacturers, affecting approval timelines.

3. Risk of Needlestick Injuries and Patient Compliance: Despite advancements, the use of needles for parenteral administration carries risks like needlestick injuries and can cause fear or discomfort, potentially leading to poor patient compliance. This challenge necessitates continuous innovation in safer and more patient-friendly delivery devices.

These drivers and challenges on the parenteral drug market is one of sustained growth, fueled by medical necessity and technological innovation. However, addressing the inherent complexities of manufacturing, stringent regulatory demands, and patient-related challenges will be crucial for broader accessibility and continued market expansion.

List of Parenteral Drug Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies parenteral drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the parenteral drug companies profiled in this report include-

• Ostuka Pharmaceutical
• Teva Pharmaceutical Industries
• Kelun Pharma
• Cook Pharmica
• Patheon
• BAG Healthcare
• Beximco Pharma
• Baxter Healthcare Corporation
• B. Braun
• Fresenius

Parenteral Drug Market by Segment

The study includes a forecast for the global parenteral drug market by type, application, and region.

Parenteral Drug Market by Type [Value from 2019 to 2031]:

• LVP Drug
• SVP Drug

Parenteral Drug Market by Application [Value from 2019 to 2031]:

• Hospital
• Medical Centers
• Others

Parenteral Drug Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Parenteral Drug Market

The parenteral drug market is experiencing dynamic growth, driven by the increasing prevalence of chronic diseases, advancements in biotechnology, and the rising demand for targeted therapies. This market, encompassing injectable drugs, plays a critical role in delivering high-potency and complex molecules, and is evolving rapidly with innovations in drug delivery systems and manufacturing processes globally.

• United States: The U.S. parenteral drug market is expanding significantly due to the increasing demand for biologics and targeted therapies, particularly for chronic diseases like cancer and diabetes. There's a notable shift towards home healthcare, driven by the development of patient-friendly self-administration devices like prefilled syringes and auto-injectors, enhancing patient convenience and reducing hospital visits.
• China: China parenteral drug market is witnessing robust growth, fueled by rising healthcare expenditure, a large aging population, and increasing prevalence of chronic diseases. Recent developments include significant investments in local manufacturing capabilities for injectable drugs, with a focus on improving new drug approval timelines and enhancing overall pharmaceutical presence.
• Germany: Germany pharmaceutical market, a key player in Europe, sees parenteral delivery rising steadily. Driven by strong biopharmaceutical investments, an aging population, and a focus on specialized therapies, there's increased capacity for complex biologics. Recent acquisitions and expansions in sterile manufacturing facilities further bolster its position in parenteral drug production.
• India: India parenteral drug market is experiencing growth driven by increased healthcare access, rising chronic disease burden, and a growing pharmaceutical manufacturing sector. Indian companies are actively launching new product lines and expanding manufacturing capabilities for injectable drugs, focusing on both domestic demand and export opportunities, indicating a dynamic market.
• Japan: Japan parenteral drug market is influenced by its aging population and a focus on innovative therapies, including gene therapies and antibody-drug conjugates, which often require parenteral administration. Recent regulatory reforms aim to streamline drug development and accelerate market access for novel medicines, indicating a push towards high-value injectable treatments.

Features of the Global Parenteral Drug Market

• Market Size Estimates: Parenteral drug market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: Parenteral drug market size by type, application, and region in terms of value ($B).
• Regional Analysis: Parenteral drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different type, applications, and regions for the parenteral drug market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the parenteral drug market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the parenteral drug market by type (LVP drug and SVP drug), application (hospital, medical centers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Parenteral Drug Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 LVP Drug: Trends and Forecast (2019-2031)
• 4.4 SVP Drug: Trends and Forecast (2019-2031)

5. Global Parenteral Drug Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Hospitals: Trends and Forecast (2019-2031)
• 5.4 Medical Centers: Trends and Forecast (2019-2031)
• 5.5 Others: Trends and Forecast (2019-2031)

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Parenteral Drug Market by Region

7. North American Parenteral Drug Market

• 7.1 Overview
• 7.2 North American Parenteral Drug Market by Type
• 7.3 North American Parenteral Drug Market by Application
• 7.4 United States Parenteral Drug Market
• 7.5 Mexican Parenteral Drug Market
• 7.6 Canadian Parenteral Drug Market

8. European Parenteral Drug Market

• 8.1 Overview
• 8.2 European Parenteral Drug Market by Type
• 8.3 European Parenteral Drug Market by Application
• 8.4 German Parenteral Drug Market
• 8.5 French Parenteral Drug Market
• 8.6 Spanish Parenteral Drug Market
• 8.7 Italian Parenteral Drug Market
• 8.8 United Kingdom Parenteral Drug Market

9. APAC Parenteral Drug Market

• 9.1 Overview
• 9.2 APAC Parenteral Drug Market by Type
• 9.3 APAC Parenteral Drug Market by Application
• 9.4 Japanese Parenteral Drug Market
• 9.5 Indian Parenteral Drug Market
• 9.6 Chinese Parenteral Drug Market
• 9.7 South Korean Parenteral Drug Market
• 9.8 Indonesian Parenteral Drug Market

10. ROW Parenteral Drug Market

• 10.1 Overview
• 10.2 ROW Parenteral Drug Market by Type
• 10.3 ROW Parenteral Drug Market by Application
• 10.4 Middle Eastern Parenteral Drug Market
• 10.5 South American Parenteral Drug Market
• 10.6 African Parenteral Drug Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunities by Type
  • 12.2.2 Growth Opportunities by Application
• 12.3 Emerging Trends in the Global Parenteral Drug Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis
• 13.2 Ostuka Pharmaceutical
  • Company Overview
  • Parenteral Drug Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Teva Pharmaceutical Industries
  • Company Overview
  • Parenteral Drug Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Kelun Pharma
  • Company Overview
  • Parenteral Drug Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Cook Pharmica
  • Company Overview
  • Parenteral Drug Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 Patheon
  • Company Overview
  • Parenteral Drug Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.7 BAG Healthcare
  • Company Overview
  • Parenteral Drug Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.8 Beximco Pharma
  • Company Overview
  • Parenteral Drug Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.9 Baxter Healthcare Corporation
  • Company Overview
  • Parenteral Drug Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.10 B. Braun
  • Company Overview
  • Parenteral Drug Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.11 Fresenius
  • Company Overview
  • Parenteral Drug Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us